Celcuity (CELC) Stock Price, News & Analysis

Company Overview

Celcuity Inc., a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, advanced or metastatic breast cancer, and metastatic castration resistant prostate cancer. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. The company was founded in 2011 and is headquartered in Minneapolis, Minnesota.

Key Stats

• Today's Range: $12.50 to $13.25
• 50-Day Range: $12.46 to $16.35
• 52-Week Range: $11.51 to $22.19
• Volume: 205,416 shs
• Average Volume: 278,728 shs
• Market Capitalization: $489.74 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $29.17
• Consensus Rating: Buy

Celcuity Stock Analysis - MarketRank™

Celcuity scored higher than 34% of companies evaluated by MarketBeat, and ranked 746th out of 956 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Buy

Consensus Rating

Celcuity has received a consensus rating of Buy. The company's average rating score is 3.14, and is based on 6 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Celcuity has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Celcuity are expected to decrease in the coming year, from ($2.59) to ($3.23) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Celcuity is -5.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Celcuity is -5.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Celcuity has a P/B Ratio of 3.27. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

9.40% of the outstanding shares of Celcuity have been sold short.

Short Interest Ratio / Days to Cover

Celcuity has a short interest ratio ("days to cover") of 12.3, which indicates bearish sentiment.

Change versus previous month

Short interest in Celcuity has recently decreased by 1.13%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Celcuity does not currently pay a dividend.

Dividend Growth

Celcuity does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

9.40% of the outstanding shares of Celcuity have been sold short.

Short Interest Ratio / Days to Cover

Celcuity has a short interest ratio ("days to cover") of 12.3, which indicates bearish sentiment.

Change versus previous month

Short interest in Celcuity has recently decreased by 1.13%, indicating that investor sentiment is improving.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Celcuity this week, compared to 2 articles on an average week.

MarketBeat Follows

1 people have added Celcuity to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Celcuity insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $5,688.00 in company stock.

Percentage Held by Insiders

15.78% of the stock of Celcuity is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

63.33% of the stock of Celcuity is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

CELC Stock Analysis - Frequently Asked Questions

How have CELC shares performed this year?

Celcuity's stock was trading at $14.57 on January 1st, 2024. Since then, CELC shares have decreased by 9.5% and is now trading at $13.19.
View the best growth stocks for 2024 here.

How were Celcuity's earnings last quarter?

Celcuity Inc. (NASDAQ:CELC) released its quarterly earnings data on Wednesday, August, 14th. The company reported ($0.62) EPS for the quarter, beating the consensus estimate of ($0.71) by $0.09.

When did Celcuity IPO?

Celcuity (CELC) raised $18 million in an IPO on Wednesday, September 20th 2017. The company issued 2,000,000 shares at $8.00-$10.00 per share. Craig-Hallum Capital Group served as the underwriter for the IPO.

Who are Celcuity's major shareholders?

Celcuity's top institutional investors include State Street Corp (2.99%), Braidwell LP (2.39%), PFM Health Sciences LP (1.92%) and Geode Capital Management LLC (1.70%). Insiders that own company stock include David Dalvey, Richard Nigon and Richard E Buller.
View institutional ownership trends.

How do I buy shares of Celcuity?

Shares of CELC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Celcuity own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Celcuity investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Netflix (NFLX), Palo Alto Networks (PANW) and ServiceNow (NOW).

Company Calendar

• Last Earnings: 8/14/2024
• Today: 11/24/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Medical laboratories
• Sub-Industry: Healthcare
• Current Symbol: NASDAQ:CELC
• CUSIP: N/A
• CIK: 1603454
• Web: www.celcuity.com
• Phone: (763) 392-0767
• Fax: N/A
• Employees: 40
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $29.17
• High Stock Price Target: $42.00
• Low Stock Price Target: $23.00
• Potential Upside/Downside: +121.1%
• Consensus Rating: Buy
• Rating Score (0-4): 3.14
• Research Coverage: 7 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($2.61)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-63,780,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -62.66%
• Return on Assets: -39.78%

Debt

• Debt-to-Equity Ratio: 0.65
• Current Ratio: 10.35
• Quick Ratio: 10.36

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.03 per share
• Price / Book: 3.27

Miscellaneous

• Outstanding Shares: 37,130,000
• Free Float: 31,271,000
• Market Cap: $489.74 million
• Optionable: Optionable
• Beta: 0.76